Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Akums Drugs and Pharmaceuticals has a current ratio of 0.00. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Akums Drugs and Pharmaceuticals has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Akums Drugs and Pharmaceuticals's Current Ratio or its related term are showing as below:
NSE:AKUMS'
s Current Ratio Range Over the Past 10 Years
Min: 1.48 Med: 2 Max: 3.95
Current: 3.25
During the past 6 years, Akums Drugs and Pharmaceuticals's highest Current Ratio was 3.95. The lowest was 1.48. And the median was 2.00.
NSE:AKUMS's Current Ratio is ranked better than 70.98% of 996
companies
in the Drug Manufacturers industry
Industry Median: 1.92
vs NSE:AKUMS: 3.25
Akums Drugs and Pharmaceuticals (NSE:AKUMS) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Akums Drugs and Pharmaceuticals Current Ratio Related Terms
Akums Drugs and Pharmaceuticals Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akums Drugs and Pharmaceuticals Current Ratio Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Akums Drugs and Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akums Drugs and Pharmaceuticals Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akums Drugs and Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where Akums Drugs and Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a Current Ratio of 0.00 as of Jun. 2026. Over the past decade, Akums Drugs and Pharmaceuticals' Current Ratio has ranged from 1.48 to 3.95. According to the industry distribution chart, Akums Drugs and Pharmaceuticals ranks #289 out of 996 companies in the Drug Manufacturers industry, placing it in the top 29%.
Is Akums Drugs and Pharmaceuticals' Current Ratio too high?
Akums Drugs and Pharmaceuticals' current Current Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 1.48 to a high of 3.95. Based on the distribution chart, Akums Drugs and Pharmaceuticals ranks #289 out of 996 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Akums Drugs and Pharmaceuticals has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Akums Drugs and Pharmaceuticals' Current Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Akums Drugs and Pharmaceuticals ranks #289 out of 996 companies for Current Ratio. This puts Akums Drugs and Pharmaceuticals in the upper half of its industry. The industry median Current Ratio is 1.92. Historically, Akums Drugs and Pharmaceuticals' own Current Ratio has ranged from 1.48 to 3.95 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 1.92, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akums Drugs and Pharmaceuticals's current Current Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akums Drugs and Pharmaceuticals stock overvalued right now?
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a current Current Ratio of 0.00. The current Current Ratio is 0.00. Akums Drugs and Pharmaceuticals' overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Akums Drugs and Pharmaceuticals (NSE:AKUMS), the current Current Ratio is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). It operates in five segments: Contract Development and Manufacturing Operations, Active Pharmaceutical Ingredient (API), Domestic Branded formulations, International Branded Formulations, and Trade generics. Key revenue is generated from Contract Development and Manufacturing Operations.
40GF Score
Get the complete analysis for NSE:AKUMS
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AKUMS has been successfully added to your 
